GlassScriptPhysician profile
Caitlin Brown
NPI 1265154439
$2,439.76
in general payments reported to CMS, 2019-2025
17 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,465 · 2024: $511 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.27 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $568.70 | 2023-2025 | Ingrezza |
| Abbvie INC. | $356.60 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $304.20 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $250.00 | 2023-2025 | Austedo, Austedo Xr |
| Alkermes, INC. | $241.72 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Idorsia Pharmaceuticals US INC | $211.57 | 2023 | Quviviq |
| Lundbeck LLC | $125.78 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $93.37 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $71.99 | 2023-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $68.16 | 2023 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $29.41 | 2023-2024 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.78 | 2025 | |
| Corium, LLC | $21.52 | 2025 | Azstarys |
| Tempus Ai, INC | $20.72 | 2024 | |
| Indivior INC. | $18.64 | 2024 | Sublocade |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.50 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $17.10 | 2024 | Invega Sustenna, Invega Trinza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.